Prostate Cancer: Anatomic Distribution, Diagnosis, and Treatment
Most Common Zones of Prostate Cancer Involvement
The peripheral zone (PZ) is the most common site of prostate cancer, accounting for approximately 70% of cases, followed by the transition zone (TZ) and central zone (CZ). 1 Importantly, TZ tumors demonstrate better clinical outcomes and prognosis compared to PZ and CZ tumors, though this zonal distinction does not currently alter standard treatment approaches 1, 2.
Key Anatomic Considerations:
- Peripheral Zone: Most common origin (70% of cancers), typically detected by digital rectal examination (DRE) and targeted biopsy
- Transition Zone: Second most common, associated with better biochemical recurrence-free survival after radical prostatectomy 2
- Central Zone: Least common site of cancer origin
Clinical Pitfall: While TZ cancers have better prognosis, they more frequently have positive surgical margins at the apico-anterior portion of the gland during prostatectomy 2. However, this zonal information adds minimal predictive value beyond standard prognostic factors and should not independently drive treatment decisions.
Diagnostic Work-Up
Initial Evaluation
A prostate biopsy decision should be based on multiple factors—not PSA alone—including DRE findings, patient age, ethnicity, comorbidities, family history, and prior biopsy results. 3, 4
PSA Considerations:
- Do not proceed with biopsy based on a single elevated PSA; verify with a second measurement 4
- Risk of cancer increases continuously even at "low" PSA values:
- PSA 0.5-1.0 ng/mL: 10% cancer risk
- PSA 2.1-3.0 ng/mL: 24% cancer risk
- PSA 4.0-10.0 ng/mL: 17-32% cancer risk 5
Biopsy Technique:
- Perform transrectal ultrasound (TRUS)-guided biopsy under antibiotic prophylaxis with local anesthesia
- Obtain minimum 10-12 cores targeting the peripheral zone at apex, mid-gland, and base 4
- For repeat biopsies: multi-parametric MRI is recommended before re-biopsy, with MRI-guided or MRI-TRUS fusion biopsy 4, 6
Pathology Reporting Requirements:
Each biopsy core must report 3, 4:
- Location
- Maximum length of cancer involvement
- Gleason score (most common and worst grades)
- ISUP grade group
- Presence of lymphovascular invasion, extraprostatic extension, intraductal carcinoma, or invasive cribriform pattern (independent predictors of metastasis and cancer-specific survival) 6
Risk Stratification and Staging
All localized prostate cancer must be classified into low-, intermediate-, or high-risk categories to guide staging investigations and treatment. 3, 4
Risk Classification (NCCN/ESMO):
| Risk Category | Criteria |
|---|---|
| Low-risk | ALL of: T1-T2a AND Gleason <7 (ISUP 1) AND PSA <10 |
| Intermediate-risk | Between low and high |
| High-risk | ANY of: T3-T4 OR Gleason ≥8 (ISUP ≥4) OR PSA >20 |
Staging Investigations by Risk Category:
Low-Risk Disease:
Intermediate-Risk Disease:
- For ISUP grade group 3: Perform cross-sectional abdominopelvic imaging and bone scan 6
- PSMA PET/CT if available (increases accuracy) 6
- For patients planned for radical radiotherapy: pelvic MRI is ideal 3
- For radical prostatectomy candidates: Discuss lymph node dissection based on nomogram estimates 3
High-Risk Disease:
- Mandatory metastatic screening with PSMA PET/CT (if available) 6
- At minimum: Bone scintigraphy AND cross-sectional abdominopelvic imaging (CT or MRI) 3, 4, 6
- Pelvic MRI should be considered 3
Important Note: PSMA PET/CT demonstrates superior sensitivity (77%) and specificity (97%) for lymph node staging compared to conventional imaging, and is more accurate than bone scan for detecting metastases 6.
Treatment by Risk Category
Low-Risk Disease (T1-T2a, Gleason <7, PSA <10)
Active surveillance is the preferred approach for low-risk prostate cancer, as no benefit for active treatment has been demonstrated in overall survival. 3, 4 The PIVOT trial showed <3% risk of death from prostate cancer at 12 years in low-risk patients, with no significant benefit from surgery 3.
Active Surveillance Protocol:
- Serial PSA monitoring
- Repeat prostate biopsies
- MRI surveillance
- Initiate treatment if Gleason score or tumor stage increases 7
Alternative Treatment Options:
Critical Consideration: Approximately one-third of patients with localized prostate cancer are appropriate for active surveillance 7. The decision should incorporate life expectancy and patient preference regarding treatment-related adverse effects.
Intermediate-Risk Disease
Treatment options include radical prostatectomy, external beam radiotherapy plus androgen deprivation therapy (ADT), or high-dose rate brachytherapy. 3, 4
Radiotherapy Approach:
- Neoadjuvant and concurrent ADT for 4-6 months should be considered 4
- External beam RT is a definitive option
Surgical Approach:
- Radical prostatectomy (open, laparoscopic, or robotic-assisted)
- Consider lymph node dissection based on nomogram risk estimates 3
For Non-Surgical Candidates:
High-Risk/Locally Advanced Disease
High-risk patients should be offered external beam radiotherapy plus hormone treatment for at least 2 years. 3, 4
Primary Treatment Options:
Radiotherapy Protocol (Preferred):
- External beam RT
- Neoadjuvant LHRH agonist therapy for 4-6 months 3, 4
- Adjuvant hormonal therapy for 2-3 years (for patients at high risk of prostate cancer mortality) 3, 4
Surgical Option (Highly Selected Cases):
Important: Primary ADT alone is NOT recommended as standard initial treatment for non-metastatic disease 4.
Post-Operative Management
Adjuvant/Salvage Radiotherapy:
- Immediate post-operative RT is NOT routinely recommended 4
- For positive surgical margins or extracapsular extension with undetectable PSA: Inform patients about pros/cons of adjuvant RT 4
- For PSA failure after radical prostatectomy: Salvage RT to prostate bed should start early (PSA <0.5 ng/mL) 4
Adjuvant Hormone Therapy:
- NOT recommended after radical prostatectomy alone 3
- Bicalutamide 150 mg daily can be considered as alternative to LHRH agonist (limited outcome data) 3
Metastatic Disease
For newly diagnosed metastatic hormone-naïve prostate cancer, continuous ADT plus androgen receptor pathway inhibitors (ARTAs) is first-line treatment. 4, 7
First-Line Treatment:
- ADT + abiraterone improves median overall survival from 36.5 to 53.3 months (HR 0.66) 7
- ADT + docetaxel for patients fit enough for chemotherapy extends survival compared to ADT alone 4, 8, 7
- Alternative ARTAs: darolutamide, enzalutamide 7
Castration-Resistant Prostate Cancer (CRPC):
- Asymptomatic/mildly symptomatic: Abiraterone or enzalutamide 4
- Bone-predominant symptomatic disease without visceral metastases: Radium-223 4
- Chemotherapy-eligible: Docetaxel 4
Bone Metastases Management:
- Denosumab or zoledronic acid for patients at high risk of skeletal-related events 3
- Denosumab superior to zoledronic acid for time to skeletal-related events (HR 0.82) but increased hypocalcemia risk (13% vs 6%) 3
- Dental evaluation required before initiating due to osteonecrosis of mandible risk 3
Treatment-Related Adverse Effects
All patients must be counseled that prostate cancer treatment may cause:
- Sexual dysfunction and erectile dysfunction (80% with surgery vs 45% with watchful waiting) 3
- Infertility
- Urinary incontinence (49% with surgery vs 21% with watchful waiting) 3
- Rectal/voiding problems 3
Consultation with both urologist and radiation oncologist is recommended to allow informed decision-making regarding treatment options and their side-effect profiles 3.
Follow-Up
- Routine DRE after local therapy is NOT required for asymptomatic patients while PSA remains controlled 4
- Prostate biopsy after radiotherapy should only be performed in men being considered for salvage local therapy 4
- Monitor for radiation enteropathy in patients with bowel symptoms post-radiotherapy 4